Indivior Pharmaceuticals, Inc. · NASDAQ:INDV
Indivior Pharmaceuticals — Q1 2024 Earnings Presentation
15 slides from Indivior Pharmaceuticals's earnings presentation, Apr 25, 2024
Slide 1: Q1 2024 Results
Q1 2024 Results April 25, 2024
Slide 2: Forward-looking Statements
Q1 2024 Results | April 25, 2024 Forward-looking Statements This presentation contains certain statements that are forward-looking. Forward-looking statements include, among other things, statements regarding strategic priorities, strategies for value creation, and operational goals; expected future
Slide 3: Mark Crossley, Chief Executive Officer
Mark Crossley Chief Executive Officer
Slide 4: Q1 2024 Financial Highlights and Key Messages
Q1 2024 Results | April 25, 2024 Q1 2024 Financial Highlights1 TOTAL NR SUBLOCADE NR REPORTED OP. / ADJ. OP. PROFIT2 $284m, 12% $179m, 36% $65m / $70m, 1% Q1 2024 Key Messages ➔ Double-digit total net revenue (NR) growth led by SUBLOCADE® ➔ SUBLOCADE sequential growth impacted by transitory items: g
Slide 5: Executing Well Against our Strategic Priorities
Q1 2024 Results | April 25, 2024 Executing Well Against our Strategic Priorities Grow Diversify Build & Optimize SUBLOCADE Revenue Progress Operating >$1.5bn Pipeline4 Model • SUBLOCADE Q1 2024 NR of $179m, • SUBLOCADE Q1 2024 ex-U.S. NR • INDV 6001 (OUD5): Initiation of • $356m of gross cash and +3
Slide 6: Confident in Medium-term Performance: Double-Digit % NR CAGR & Margin Expansion
Q1 2024 Results | April 25, 2024 Confident in Medium-term Performance: Double-Digit % NR CAGR & Margin Expansion Total Net Revenue Key Top-line Drivers: (NR$ in USD millions) ◆ SUBLOCADE >$1.5 bn potential annual NR – expected to reach $1 bn NR run-rate by the end of 2025 FY 24 Guidance ◆ PERSERIS p
Slide 7: Ryan Preblick, Chief Financial Officer
Ryan Preblick Chief Financial Officer
Slide 8: Q1 2024 Financial Highlights
Q1 2024 Results | April 25, 2024 Q1 2024 Financial Highlights Key Takeaways: Operating Results: (vs. Q1 2023 unless otherwise indicated) (Reported and Adjusted1) ➤ Q1 2024 total NR growth of 12% (12% at constant FX) $ mil Q1 24 Q1 23 Change U.S. NR up 15% Net Revenue (NR): 284 253 12% ROW NR dow
Slide 9: Cash & Borrowing Position
Q1 2024 Results | April 25, 2024 Cash & Borrowing Position Cash & Borrowings: Key Takeaways: Cash & investments of $356m1 ($ in mil.) Mar. 31, 2024 Dec. 31, 2023 ➤ Scheduled settlement payments totaling Cash & Cash Equivalents 248 316 $70m during Q1 2024 ➤ Approximately $36m used for share repurchas
Slide 10: FY 2024 Guidance Reconfirmed
Q1 2024 Results | April 25, 2024 FY 2024 Guidance Reconfirmed1 Top-Line Assumptions: ($ in mil.) ➤ Underlying U.S. BMAT3 growth of mid- to high-single digits Total Net Revenue $1,240m to $1,330m (up 18% at mid-point) ➤ OPVEE NR inclusive of $8m from BARDA contract ➤ U.S. SUBOXONE4 Film NR: Key Produ
Slide 11: U.S. Primary Listing Update
U.S. Primary Listing Update
Slide 12: Pursuing Shareholder Approval to Effect a U.S. Primary Listing
Q1 2024 Results | April 25, 2024 Pursuing Shareholder Approval to Effect a U.S. Primary Listing Net Revenue by Geography Background & Context Expected Benefits Next Steps • U.S. NR represents 84% of • Elevate profile as addiction • Broad indications of 16% total NR (FY 2023) treatment leader with a
Slide 13: APPENDIX
APPENDIX
Slide 14: Q2 2024 Capital Markets Calendar
Q1 2024 Results | April 25, 2024 Q2 2024 Capital Markets Calendar Date Key Event Apr. 25th – Apr. 29th Q1 Results & Investor Roadshow (Virtual) May 7th U.K. Investor Roadshow (London) May 9th Annual General Meeting May 23rd General Meeting – Shareholder Vote on Effecting U.S. Primary (London) May 23
Slide 15: Financial Reconciliations
Q1 2024 Results | April 25, 2024 Financial Reconciliations Reconciliation of gross profit to adjusted gross profit 2024 2023 For the three months ended March 31 $m $m Gross profit 238 214 Exceptional items and other adjustments in cost of sales 3 — Adjusted gross profit 241 214 We define adjusted gr
Indivior Pharmaceuticals — Q1 2024 Earnings Presentation on 6ix